特發性肺纖維化市場：依藥物、給藥途徑、通路及地區分類

Idiopathic Pulmonary Fibrosis Market, By Drug, By Route of Administration, By Distribution Channel, and By Geography

出版日期: 2025年07月01日 | 出版商:

Coherent Market Insights | 英文 339 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

特發性肺纖維化市場規模預計在 2025 年為 49.5 億美元，預計到 2032 年將達到 88.759 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 8.7%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	49.5億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	8.70%	2032年價值預測	88.759億美元

特發性肺纖維化 (IPF) 是一種特殊類型的慢性、進行性纖維化間質性肺炎，病因不明，主要影響老年人的肺部，其組織病理學和/或放射學特徵與進行性間質性肺炎 (UIP) 相似。 IPF 的診斷需要排除其他類型的間質性肺炎，包括其他特發性間質性肺炎 (IIP) 以及與環境暴露、藥物或結締組織疾病相關的間質性肺部疾病 (ILD)。

市場動態

特發性肺纖維化盛行率的不斷上升預計將推動市場成長。例如，根據美國國家醫學圖書館2021年7月發布的報告，2020年全球特發性肺纖維化的盛行率為每10萬人13-20人。在美國，2020年約有10萬人受其影響，每年診斷出3萬至4萬例新病例。

印度國家生物技術資訊中心發布的報告顯示，2021年，印度特發性肺纖維化的盛行率將達到13.7%左右。

此外，特發性肺纖維化盛行率的不斷上升促使主要市場參與者專注於推出新產品，預計這將在預測期內推動市場成長。例如，2022年5月，學名藥和生物相似藥領域的全球領導者山德士宣布將在美國特發性Pirfenidone的學名藥。吡非尼酮是第一個獲得AB類上市許可（完全可互換）的抗體藥物，與生物技術公司基因泰克的Esbriet等效，用於治療特發性肺纖維化(IPF)患者。該學名藥藥物將透過專科藥房開立處方給患者。

本次調查的主要特點

本報告對全球特發性肺纖維化市場進行了詳細分析，並以 2024 年為基準年，提供了預測期 2025-2032 的市場規模（百萬美元）和年複合成長率（CAGR%）。
它還揭示了各個領域的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
本研究基於公司亮點、產品系列、關鍵亮點、財務績效和策略等參數，對全球特發性肺纖維化市場的主要企業進行了分析。本研究涵蓋的主要企業包括基因泰克公司 (Genentech, Inc.)、阿斯特捷利康 (AstraZeneca)、Blade Therapeutics、百時美施貴寶公司 (Bristol-Myers Squibb Company)、西普拉公司 (Cipla Inc.)、羅氏製藥公司 (F. Hoffmann-La Roche)、西普拉公司 (Cipla Inc.)、羅氏製藥公司 (F. Hoffmann-La Roche)、默克理克 (Ciplaim)、Gicicoan (F. Hoffmann-La Roche)、默克理克公司 (Nicigos) 公司、加拉瓦戈斯公司 (Micico)、默克科Co., Inc.)、Promedior 公司、Prometic Life Sciences 公司、大熊製藥 (印度) 私人有限公司 (Daewoong Pharmaceutical (India) Pvt Ltd)、山德士國際有限公司 (Sandoz International GmbH，諾華公司) 和 Algernon Pharmaceuticals 公司。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
全球特發性肺纖維化市場報告涉及該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過用於分析全球特發性肺纖維化市場的各種策略矩陣更輕鬆地做出決策。

Genentech, Inc.
Boehringer Ingelheim International GmbH.
Avalyn Pharma, Inc.
AstraZeneca
Blade Therapeutics
Bristol-Myers Squibb Company
Cipla Inc.
F. Hoffmann-La Roche
FibroGen, Inc.
Galapagos NV
MediciNova, Inc.
Merck & Co., Inc.
Promedior, Inc.
Prometic Life Sciences Inc.
Daewoong Pharmaceutical（India）Pvt Ltd.
Sandoz International GmbH（Novartis）
Algernon Pharmaceuticals Inc.

第9章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI2466

Idiopathic Pulmonary Fibrosis Market is estimated to be valued at USD 4,950 Mn in 2025 and is expected to reach USD 8,875.9 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 4,950 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.70%	2032 Value Projection:	USD 8,875.9 Mn

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.

Market Dynamics

Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.

According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.

Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech's, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies.

Key features of the study

This report provides in-depth analysis of the global Idiopathic pulmonary fibrosis market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market.

Market Segmentation

Global Idiopathic pulmonary fibrosis market, By Drug
- Pirfenidone
- Nintedanib
- Others (Interferon gamma-1b and Others)
Global Idiopathic pulmonary fibrosis market, By Route of Administration
- Oral
- Parenteral
Global Idiopathic pulmonary fibrosis market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Idiopathic pulmonary fibrosis market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Genentech, Inc.
- Boehringer Ingelheim International GmbH
- Avalyn Pharma, Inc.
- AstraZeneca
- Blade Therapeutics
- Bristol-Myers Squibb Company
- Cipla Inc.
- Hoffmann-La Roche
- FibroGen, Inc.
- Galapagos NV
- MediciNova, Inc.
- Merck & Co., Inc.
- Promedior, Inc.
- Prometic Life Sciences Inc.
- Daewoong Pharmaceutical (India) Pvt Ltd.
- Sandoz International GmbH (Novartis)
- Algernon Pharmaceuticals Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Product Launches
- Merger, Acquisition, Collaboration
- Regulatory Guideline and Compliances
- Key Developments
- Market Trends
- PEST Analysis
- Epidemiology
- PORTER's Analysis
- Regulatory Scenario
- Brand Analysis
- Pricing Analysis
- Pipeline Analysis

4. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pirfenidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Nintedanib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others (Interferon gamma-1b and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2020 - 2032, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Avalyn Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Blade Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
FibroGen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Galapagos NV
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
MediciNova, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Promedior, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Prometic Life Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Daewoong Pharmaceutical (India) Pvt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sandoz International GmbH (Novartis)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Algernon Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies